Back to top
more

Lineage Cell Therapeutics (LCTX)

(Delayed Data from AMEX)

$1.54 USD

1.54
1,209,892

+0.02 (1.32%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $1.55 +0.01 (0.65%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lineage Cell Therapeutics, Inc. [LCTX]

Reports for Purchase

Showing records 1 - 20 ( 114 total )

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/06/2026

Company Report

Pages: 7

The Palpable Wait on Roche and Signfiicant Pipeline/Tech Advances; 2025 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

01/06/2026

Daily Note

Pages: 4

Cell Therapy Platform Broadens with Gene-Edited Hypoimmune iPSC Line

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/24/2025

Daily Note

Pages: 5

Tangible Evidence of Continued OpRegen Progress at Global Partner Roche

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/07/2025

Company Report

Pages: 8

One Iota of Roche Visibility Should be Transformative for Shares; 3Q25 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

09/08/2025

Daily Note

Pages: 6

New Islet Cell Program to Get Off the Ground; If it Works, a Game Changer for Many

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/26/2025

Daily Note

Pages: 6

Turning Up the Volume on Hearing Loss Program; Another Savvy Strategic Move by Lineage

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/13/2025

Company Report

Pages: 6

2Q25 Results; GMP Manufacturing Platform Positions for Multi-Program Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/04/2025

Daily Note

Pages: 6

First OPC1 Patient Dosed Plus Early Derivative RPE Cell Approach Validation

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/23/2025

Company Report

Pages: 7

Wow; OpRegen Durability Nothing to Blink At; Major Shot Across the Bow of GA Competitors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/14/2025

Company Report

Pages: 6

1Q25 Results; Eyes on OpRegen With 3-Year Data Next Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/11/2025

Company Report

Pages: 7

2024 Results; Roche Data to Fuel Momentum

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/11/2025

Company Report

Pages: 8

Without Further Ado, We Welcome OPC1 Back to the Clinic; Upcoming OpRegen Data Major Driver

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

01/31/2025

Company Report

Pages: 6

Lineage''s Vision Remains 20/20 as External Validation Behind RPE Cell Therapy Builds

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/04/2024

Company Report

Pages: 10

Pay Attention; Major Roche Data Could Come at Any Time; Target Upped to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/09/2024

Company Report

Pages: 10

2Q24 Results; Waiting on Roche Data as Major Driver; OPC1 Study Expected in Near-Term

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/10/2024

Company Report

Pages: 10

1Q24 Results; Roche Signs New Services Agreement On Top of Existing Global Partnership

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/06/2024

Company Report

Pages: 10

Seeing Continues to Be Believing; Roche Presents Impressive 24-Month OpRegen Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/12/2024

Company Report

Pages: 4

BUY: Spends $25M in 2023, and $35M in Cash Plus $14M - Funded through 3Q2025

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/08/2024

Company Report

Pages: 9

2023 Results; Updated OpRegen Durability Impresses Solidifying Roche''s Global Partner Role

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party